PMA device
CyPass System 241-S
Alcon Research, Ltd. · Intraocular Pressure Lowering Implant (OGO, Class III) · First FDA decision Nov 3, 2016, newest May 29, 2018Glaucoma
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
PMA pathway
Device trials
7
Naming "CyPass"
MAUDE reports
836
Brand "CyPass", since 2015
PubMed studies
94
Mentioning "CyPass"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing CyPass System 241-S
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
- CyPass System 241-SPMA supplement
P150037-S007 · Decided May 29, 2018 · 306 days after receipt · Normal 180 Day Track No User Fee
Device type: Intraocular pressure lowering implant (OGO) · Ophthalmology
- CYPASS SYSTEMPMA supplement
P150037-S002 · Decided Mar 15, 2017 · 201 days after receipt · Normal 180 Day Track No User Fee
Device type: Intraocular pressure lowering implant (OGO) · Ophthalmology
- CyPass SystemPMA supplement
P150037-S001 · Decided Nov 3, 2016 · 71 days after receipt · Normal 180 Day Track No User Fee
Device type: Intraocular pressure lowering implant (OGO) · Ophthalmology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Implantable Pulmonary Artery Pressure Sensors for Heart Failure ManagementNational determinationOn the books20.36Updated Oct 6, 2026
- Implantable Pulmonary Artery Pressure Sensors for Heart Failure ManagementNational analysisReview closedCAG-00466NUpdated Sep 18, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "CyPass", any status and sponsor, newest update first.
Alcon ResearchNot on our public-company list
NCT04629521 · 54 participants · Start Dec 21, 2020 · Primary completion Apr 5, 2023
Device: CyPass Micro-Stent · For: Primary Open Angle Glaucoma; Cataract
Sites: Glendale, Arizona; Orange, California; Fort Collins, Colorado · 12 sites in all
- Post Approval Study of the CyPass SystemTerminated
Alcon ResearchNot on our public-company list
NCT03273907 · 79 participants · Start Oct 12, 2017 · Primary completion Aug 31, 2021
Device: CyPass Micro-Stent implanted with CyPass 241-S applier · For: Primary Open-angle Glaucoma; Cataract
Sites: Phoenix, Arizona; Orange, California; Fort Collins, Colorado · 20 sites in all
- A Study to Assess Long-Term Safety of the CyPass Micro-Stent in Patients Completing the COMPASS TrialPivotal-lookingCompleted
Alcon ResearchNot on our public-company list
NCT02700984 · 282 participants · Start Mar 30, 2016 · Primary completion Apr 18, 2018
Device: CyPass Micro-Stent · For: Primary Open Angle Glaucoma (POAG)
Sites: Glendale, Arizona; Fayetteville, Arkansas; La Jolla, California · 22 sites in all
4 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "CyPass", and for the whole product code for context.
This brand
836 reports: 107 malfunction, 729 injury, 0 death
Whole product code OGO
2,634 reports: 667 malfunction, 1,967 injury, 0 death
Newest reports for this brand
- CYPASS SYSTEMInjury
ALCON RESEARCH, LLC - ALCON PRECISION DEVICE
2523835-2026-00613 · Received Jun 18, 2026 · Event dated May 2, 2018
Device type: Intraocular Pressure Lowering Implant (OGO)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Corneal Endothelial Cell Loss
- CYPASS SYSTEMInjury
2523835-2026-00478 · Received May 11, 2026 · Event dated Jul 1, 2025
Device type: Intraocular Pressure Lowering Implant (OGO)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Appropriate Clinical Signs, Symptoms and Conditions Term/Code Not Available
- CYPASS SYSTEMInjury
ALCON RESEARCH, LLC - ALCON PRECISION DEVICE
2523835-2026-00462 · Received May 7, 2026 · Event dated Jan 7, 2026
Device type: Intraocular Pressure Lowering Implant (OGO)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Adhesion(s); Blurred Vision; Eye Pain; Intraocular Pressure Decreased
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0185-2019 · Started Aug 28, 2018 · Posted by FDA Oct 23, 2018
Reason given: Analysis of the completed dataset from the COMPASS-XT long-term study showed that the CyPass Micro-Stent group experienced statistically significant endothelial cell loss (ECL) compared to the group who underwent cataract surgery alone.
Cause as FDA categorized it: Device Design · Device type: Intraocular Pressure Lowering Implant (OGO)
Z-0186-2019 · Started Aug 28, 2018 · Posted by FDA Oct 23, 2018
Reason given: Analysis of the completed dataset from the COMPASS-XT long-term study showed that the CyPass Micro-Stent group experienced statistically significant endothelial cell loss (ECL) compared to the group who underwent cataract surgery alone.
Cause as FDA categorized it: Device Design · Device type: Intraocular Pressure Lowering Implant (OGO)
Z-0187-2019 · Started Aug 28, 2018 · Posted by FDA Oct 23, 2018
Reason given: Analysis of the completed dataset from the COMPASS-XT long-term study showed that the CyPass Micro-Stent group experienced statistically significant endothelial cell loss (ECL) compared to the group who underwent cataract surgery alone.
Cause as FDA categorized it: Device Design · Device type: Intraocular Pressure Lowering Implant (OGO)
1 more recall records with a free account
Published research
The most relevant PubMed records for "CyPass"[tiab]. The summary above synthesizes these.
- [Micro-invasive glaucoma surgery].
Khalilova TA, Zaitseva AA, Koveshnikov AI · Vestn Oftalmol · 2023English Abstract
- Complications after CyPass® Micro-Stent explantation: a case series.
Habbe KJ, Kohlhaas M, Fili S · Int Ophthalmol · 2024
- Suprachoroidal shunts.
Vinod K · Curr Opin Ophthalmol · 2018Review
- Minimally Invasive Glaucoma Surgery: A Review of the Literature.
Balas M, Mathew DJ · Vision (Basel) · 2023Review
- [Explantation of the CyPass implant in a case series of patients with corneal decompensation].
Fili S, Seddig S, Vastardis I, et al. · Ophthalmologe · 2021
- Chronic Granulomatous Inflammation after CyPass® Implantation.
Schoelles KJ, Anton A, Auw-Haedrich C · Ocul Oncol Pathol · 2020Case Reports
- Corneal endothelial safety profile in minimally invasive glaucoma surgery.
Ahmed IIK, Sheybani A, De Francesco T, et al. · J Cataract Refract Surg · 2024Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- [One-year results after Cypass implantation].
Fili S, Seddig S, Papadopoulou E, et al. · Ophthalmologe · 2019
- [CyPass microstent trimming with special cutting forceps : Video article].
Rose C, Schargus M · Ophthalmologe · 2022Review
- Ultrastructural analysis of explanted CyPass microstents and correlation with clinical findings.
Hübner L, Schlötzer-Schrehardt U, Weller JM, et al. · Graefes Arch Clin Exp Ophthalmol · 2022
- Comparing iStent versus CyPass with or without phacoemulsification in patients with glaucoma: a meta-analysis.
Mahdavi Fard A, Patel SP, Pourafkari L, et al. · Ther Adv Chronic Dis · 2019
Other devices of this type
Also filed under product code OGO.
- iStent Trabecular Micro-Bypass Stent System, iStent inject Trabecular Micro-Bypass System, iStent inject W Trabecular MiGlaukos Corporation · PMA 2022
- iStent inject Trabecular MicroBypass SystemGlaukos Corporation · PMA 2025
- Hydrus MicrostentAlcon Research, LLC · PMA 2025
- iStent inject® W Trabecular Micro-Bypass System Model iS2Glaukos Corporation · PMA 2025
- Glaukos Trabecular Micro Bypass Stent Model GTS100R/LGlaukos Corporation · PMA 2013
- CyPass Micro-StentAlcon Research, Ltd. · PMA 2020
- iStent® Trabecular Mjcro-Bypass Stent System, Model GTS100Glaukos Corporation · PMA 2024
- Hydrus MicrosentAlcon Research, LLC · PMA 2021
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.